Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in combination with endocrine therapy improve the outcomes of patients with hormone-receptor (HR)-positive, HER2-negative advanced breast cancer and can be used early as first-line treatment or deferre...
[8]Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Breast Care (Basel). 2016 Jun;11(3):167-73. doi: 10.1159/000447284. Epub 2016 Jun 22. PMID: 27493615; PMCID: PMC4960359. [9]姜秀,赵文辉.CDK4/6...
【文献精选——文献精读】CDK4/6 inhibitors in breast cancer: spotting the difference(乳腺癌中CDK4/6抑制剂的差异) Dalpiclib的3期研究加强了CDK4/6抑制剂对部分转移性乳腺癌患者的疗效;有了这些抑制剂,需要更多的证据来帮助指导治疗决策。 转移性乳腺癌(MBC)在很大程度...
[4]Dukelow T, Kishan D, Khasraw M, et al. CDK4/6 inhibitors in breast cancer[J]. Anti-cancer drugs. 2015;26(8):797-806. [5]Schoninger SF and Blain SW. The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer[J]. Mol Cancer Ther. 2020;19(1):3-12...
[3]Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis.2022 ESMO abstract 169P. [4]Dukelow T, Kishan D, Khasraw M, et al. CDK4/6 inhibitors in breast cancer[J]. Anti-cancer drugs. 2015...
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in combination with endocrine therapy improve the outcomes of patients with hormone-receptor (HR)-positive, HER2-negative advanced breast cancer and can be used early as first-line treatment or deferred to second-line treatment. Randomized data...
幸运地是, CDK4/6抑制剂终于诞生。它的出现深刻地改变了目前全世界乳腺癌治疗的策略,为那些渴求生命的乳腺癌患者更多生命选择。 参考文献: [1] Malumbres, M (2007). CDK inhibitors in cancer therapy: what is next? TRENDS in Pharmacological Sciences Vol.29 No.1. 16-21 ...
[3]Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis.2022 ESMO abstract 169P. [4]Dukelow T, Kishan D, Khasraw M, et al. CDK4/6 inhibitors in breast cancer[J]. Anti-cancer drugs. 2015...
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. The SONIA study shows that early use of inhibitors that target both CDK4 and CDK6 (hereafter, CDK4/6) in metastatic breast cancer prolongs time on treatment but does not improve patient outcomes. Postponing innovative trea...
Systemic therapy for hormone receptor positive /human epidermal growth factor receptor 2 negative early stage and metastatic breast cancer. CA Cancer J Clin 2023;1-36. 8. O'Sullivan CC, Clarke R, Goetz MP, Robertson J. Cyclin-dependent kinase 4/6 inhibitors for treatment of hormone receptor-...